WilmerHale Advises Nodexus in $30M Series A Venture Financing

WilmerHale Advises Nodexus in $30M Series A Venture Financing

Firm News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
WilmerHale has played a leading role in shaping the rules that govern the US financial services industry.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Life Sciences

WilmerHale represented Nodexus Inc., an emerging leader in the development of automated live cell characterization and isolation technologies, in its $30M Series A financing that will allow the company to expand the manufacturing of its flagship NX One platform as well as build its commercialization capabilities and pipeline to meet an increasing demand.

The NX One system provides affordable walk-up usable automated single-cell sorting and dispensing to enable deployment into any lab working on bioprocessing, cancer biology research, gene editing and other expanding applications. The Series A funding will allow Nodexus to substantially grow its team and support its mission to “democratize biological tools.”

The WilmerHale team representing Nodexus was led by Joe Wyatt and included Molly Holsinger, Elise Brumbach and Sharon Baek.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel